Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is focused on improving the early detection and management of cancer and other chronic diseases through diagnostics telehealth programs. Its lead product, Aristotle, is a mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. The Care Oncology Clinic offers a supervised treatment regimen for people diagnosed with cancer of any type or stage. AVRT is a physician-led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Its program includes a comprehensive online health evaluation; bloodtests to measure markers of inflammation and metabolism; an initial physician consultation; regular physician follow-up appointments and interval screening. Its additional cancer diagnostics include ColonSentry and the Prostate Health Index.


TSX:SZLS - Post by User

Comment by LithLoveron Aug 18, 2022 10:32am
102 Views
Post# 34904646

RE:News release

RE:News release This wasn't put it out for shareholders.  This was put out to Mercer, Employer Groups, Front line worker associations etc.  It is a North American news release that says we now have everything in place to take on employer groups all the way thru Aristotle, COC, AVRT and TREAT.


From the Q1 call back in May:

We're back partnering with some innovative clinical groups. This is where we have typically be -- as these groups begin to come back on stream, get back to normal business. They are obviously open to this again. This includes the employer base. And there will be more to hear about this as we move out over the next months.  

We're getting to speak with larger and larger groups as it moves on out. Why? Not only because of what I've just gone through, but also because we have the infrastructure. In fact, we're one of the very few groups that has the infrastructure that actually can do what we're setting out to do.

We'll be publishing additional data on this as we go out through the year.



brad129 wrote: Looks like another informative but useless NR, hasn't brought any action.

usually we get one of these prior to a financing so that's probably coming.


<< Previous
Bullboard Posts
Next >>